[Value of scintigraphy with 99mTc-MIBI in the diagnosis and follow-up of Hodgkin's and non-Hodgkin's lymphomas]

Rev Esp Med Nucl. 2000 Apr;19(2):85-91.
[Article in Spanish]

Abstract

This work aimed to assess the utility of 99mTc-MIBI scintigraphy in the diagnosis and follow-up of lymphoma patients. Seventy-two patients with a previous diagnosis of lymphoma (41 with Hodgkin's and 31 with non-Hodgkin's disease) and a control group of 8 patients with palpable lymph nodes and a negative diagnosis of lymphoma based on the clinical examination, chest x-ray, lymphography, ultrasounds and biopsy were studied. Whole body scintigraphies were performed 20 min and 2 h after i.v. administration of 740 MBq of 99mTc-MIBI. The joint result of the already mentioned standard diagnostic tests was considered as the confirmation criterion. A sensitivity, specificity and accuracy of 96,2%, 100% and 97,4% respectively were obtained. Kappa coefficient was k = 0,94 +/- 0,11.

Conclusion: Scintigraphy with 99mTc-MIBI is a useful tool for the diagnosis and follow-up of lymphomas regardless of their classification.

Publication types

  • Comparative Study

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Castleman Disease / diagnostic imaging
  • Child
  • Child, Preschool
  • Evaluation Studies as Topic
  • Female
  • Follow-Up Studies
  • Hodgkin Disease / diagnostic imaging*
  • Humans
  • Lymphadenitis / diagnostic imaging
  • Lymphoma, Non-Hodgkin / diagnostic imaging*
  • Male
  • Middle Aged
  • Radionuclide Imaging
  • Sensitivity and Specificity
  • Technetium Tc 99m Sestamibi*

Substances

  • Technetium Tc 99m Sestamibi